

Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

Clemens Giessen¹, Ruediger Paul Laubender², Donna Pauler Ankerst³, Sebastian Stintzing¹, Dominik Paul Modest¹, Ulrich Mansmann², and Volker Heinemann¹

Abstract

Purpose: To evaluate progression-free survival (PFS) as a potential surrogate endpoint (SEP) for overall survival (OS) in metastatic colorectal cancer (mCRC) with a focus on applicability to trials containing targeted therapy with anti-VEGF- or anti-EGF receptor (EGFR)-directed monoclonal antibodies.

Experimental Design: A systematic literature search of randomized trials of first-line chemotherapy for mCRC reported from January 2000 to January 2012 was conducted. Adjusted weighted linear regression was used to calculate correlations within PFS and OS (endpoints; R_{EP}) and between treatment effects on PFS and on OS (treatment effects; R_{TE}).

Results: Fifty trials reflecting 22,736 patients met the inclusion criteria. Correlation between treatment effects on PFS and OS and between the endpoints PFS and OS was high across all studies ($R_{TE} = 0.87$, $R_{EP} = 0.86$). This was also observed in chemotherapy-only trials ($R_{TE} = 0.93$, $R_{EP} = 0.81$) but less so for trials containing monoclonal antibodies ($R_{TE} = 0.47$; $R_{EP} = 0.52$). Limiting the analysis to bevacizumab-based studies (11 trials, 3,310 patients) again yielded high correlations between treatment effects on PFS and on OS ($R_{TE} = 0.84$), whereas correlation within PFS and OS was low ($R_{EP} = 0.45$). In 7 trials (1,335 patients) investigating cetuximab- or panitumumab-based studies, contrasting correlations with very wide confidence intervals were observed ($R_{TE} = 0.28$; $R_{EP} = 0.96$).

Conclusions: PFS showed consistently high correlation with OS of an order that would justify its use as an SEP in chemotherapy regimens. For validation of surrogacy in anti-VEGF and anti-EGFR-directed therapies, further research and a larger set of trials is needed. *Clin Cancer Res*; 19(1); 225–35. ©2012 AACR.

Introduction

With the widespread use of monoclonal antibodies in the treatment of metastatic colorectal cancer (mCRC) and median survival times in excess of 20 months, surrogate endpoints (SEP) for treatment activity have become a popular and timely topic (1–9). This is not only because the historically favored hard endpoint of overall survival (OS) now takes longer to measure, but also because it is prone to be influenced by subsequent lines of therapies and cross-

over designs more commonly encountered in contemporary trials (9, 10).

SEPs that are reached in shorter duration and can be agreed on by consensus as replacements for OS provide a solution to some of the difficulties surrounding the feasibility of OS for trials; among these, progression-free survival (PFS) has taken center stage (3, 4, 11–14). Piedbois and Croswell proposed the definition that "a surrogate endpoint is an endpoint that can be used as a substitute for the true endpoint" (4). The U.S. Food and Drug Administration states that "an acceptable SEP should be able reasonably likely (...) to predict the clinical benefit on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity" (12, 15). However, validation of SEPs has encountered controversy among statisticians, so that to date no formal universally agreed-upon empirical criteria for SEPs exist (3–6, 11, 13, 16–19).

For years, overall response rate (ORR) and PFS have been widely used as primary endpoints in mCRC and in other cancer entities because of earlier assessments showing independence to further-line therapies (1, 5, 6). PFS is currently used in most mCRC-trials as the primary endpoint but has not yet been validated as a surrogate for OS for studies involving monoclonal antibodies, such

Authors' Affiliations: ¹Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center; ²Institute of Medical Informatics, Biometry, and Epidemiology (IBE), Faculty of Medicine, Ludwig Maximilian University of Munich; and ³Department of Mathematics, Technical University of Munich, Munich, Germany

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Clemens Giessen, Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Marchioninistrasse 15, Munich 81377, Germany. Phone: 49-89-7095-2208; Fax: 49-89-7095-5256; E-mail: clemens.giessen@med.uni-muenchen.de

doi: 10.1158/1078-0432.CCR-12-1515

©2012 American Association for Cancer Research.

Translational Relevance

Progression-free survival (PFS) is widely adopted as the primary endpoint in clinical trials for metastatic colorectal cancer (mCRC) but has neither been investigated nor validated as a surrogate endpoint (SEP) for overall survival (OS) in treatments incorporating anti-VEGF and anti-EGF receptor-directed monoclonal antibodies. This literature-based analysis of 50 first-line trials for mCRC explored the applicability of PFS as a SEP for OS in the era of targeted chemotherapy regimens. We confirmed previous literature-based and individual patient-based analyses indicating PFS as an applicable SEP for OS in chemotherapy-only trials. Analysis of published trials containing bevacizumab further suggested PFS to be a suitable SEP for chemotherapy- and bevacizumab-trials. On the basis of the present study, we encourage the investigation of additional endpoints incorporating tumor- or patient-related biomarkers and the confirmation at the individual patient level.

as bevacizumab, cetuximab, and panitumumab. The purpose of this study was to conduct a comprehensive literature-based quantitative review to determine whether PFS is correlated with OS in first-line chemotherapy trials

for mCRC in the era of VEGF- and EGF receptor (EGFR)-targeting drugs, thus increasing its scope as a SEP for OS in mCRC.

Materials and Methods

Literature search and data extraction

Randomized controlled trials for previously untreated patients who underwent first-line chemotherapy for mCRC published between January 2000 and January 2012 were identified through a systematic search in the National Library of Medicine medical literature database via PubMed gateway, Excerpta Medica Database (EMBASE), and the Cochrane Library using the keywords "metastatic colorectal cancer" and "first-line randomized trials." In addition, abstracts presented at the annual meetings of the American Society of Clinical Oncology and the European Society for Medical Oncology between January 2000 and January 2012 and bibliographies of published overviews were examined (6, 20). Only publications in English were included. Further inclusion criteria were a sample size of at least 100 patients per trial and reports of either PFS or time to progression (TTP) along with OS.

Exclusion criteria were trials containing patients with locally advanced, unresectable disease or with previous chemotherapy for metastatic disease, trials investigating surgical resection of resectable/unresectable metastatic





Figure 1. Literature search and selection of articles. PubMed, National Library of Medicine, NLM database; Cochrane, The Cochrane Library from The Cochrane Collaboration; HA, hepatic arterial infusion; RFA, radio frequency ablation; HIPEC, hyperthermic intraperitoneal chemotherapy; ASCO, American Society of Clinical Oncology; ESMO, European Society of Medical Oncology.

Figure 2. PFS (months) versus OS (months) classified by treatment. Symbol size is proportional to number of patients.



disease, trials limited to elderly/younger patients, pooled data reports or noninterventional trials (registry data), and trials using additional hepatic chemotherapy infusion. Trials involving nonapproved drugs for mCRC by the European Medical Association (EMA), such as raltitrexed, pemetrexed, and trimetrexate or containing patients with gastrointestinal cancers other than colorectal cancer were not considered. From trials comparing maintenance, stop-and-go-strategies (including fluoropyrimidine maintenance treatment), or intermittent chemotherapy versus

continuous chemotherapy, only results from the latter treatment arms were included.

Because at present time the anti-EGFR antibodies cetuximab and panitumumab are only registered for patients with KRAS wild-type tumors (KRAS-wt), trials containing 1 of 2 drugs and that did not report KRAS-mutation status were excluded (1 trial excluded). Results from KRAS-mutant patients (KRAS-mut) who underwent chemotherapy with anti-EGFR-directed monoclonal antibodies were not included in the analysis (9 trial arms excluded). With KRAS

Table 1. Correlation between treatment effects on PFS and treatment effects on OS (R_{TE}) and between PFS and OS (R_{EP})

	No. pts	No. trials/ trial arms	R_{TE}	95% CI	R_{EP}	95% CI
All treatments	22,736	50/102	0.87	0.67–0.93	0.86	0.79–0.91
Chemotherapy-only	17,887	40/74	0.93	0.49–0.97	0.81	0.71–0.88
Oxaliplatin-based	10,060	31/44	0.68	0.41–0.85	0.69	0.36–0.87
Irinotecan-based	7,301	24/36	0.82	0.52–0.95	0.74	0.59–0.86
Chemotherapy and antibody	4,849	19/28	0.47	0.05–0.72	0.52	0.09–0.88
Chemotherapy and bevacizumab	3,310	11/17	0.84	0.05–0.94	0.45	0.00–0.84
Chemotherapy and cetuximab or panitumumab	1,335	7/9	0.28	–0.87–0.92	0.96	–0.76–1.00




Figure 3. Treatment effects (log ORs) on PFS versus OS according to treatment type. The solid line is the regression line; dotted lines indicate pointwise 95% CIs. Symbol size is proportional to number of patients. Trial arms using comparable treatment regimens were summarized.

mutational status also currently undergoing discussion as a prognostic factor for OS in chemotherapy-only treatment, control was needed to avoid selection-bias resulting from KRAS-wt and/or KRAS-mut patients included in control arms not containing cetuximab and panitumumab. Therefore, KRAS-independent results were used for analyses of within treatment surrogacy (R_{EP}) in chemotherapy-only trial arms. For at the trial level surrogacy (R_{TE}) analyses, results according to KRAS-status were used in studies investigating anti-EGFR-directed agents. Four investigators (C. Giessen, S. Stintzing, D.P. Modest, and V. Heinemann) reviewed data for inclusion and exclusion, following the review process in Fig. 1 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (21).

For each trial, reported data on sample size, chemotherapy regimens, median PFS (months), and median OS (months) were extracted for all treatment arms using published data. A total of 7 trials used TTP as the primary endpoint. In contrast to PFS, TTP uses disease progression as the only event of interest and disregards death from any cause. Because both endpoints, TTP and PFS, are unaffected by subsequent therapies, they were used exchangeably for this analysis and were referred to as PFS as previously conducted in similar meta-analyses of colorectal and metastatic breast cancer (19, 22, 23).


Statistical methods

Two correlations were calculated between summary statistics to assess surrogacy based on aggregated data (6, 23–25). Correlations were conducted according to treatment class, defined as comparable chemotherapy regimens using the same cytotoxic drugs or monoclonal antibodies, using weighted linear regression with log transformation of all endpoints and weights proportional to the sample sizes.

The first approach, termed within treatment surrogacy, computed the correlation between median PFS, the potential SEP, and median OS, and the relevant endpoint reported for the same study arm (arm by arm analysis). The correlation is evaluated over all treatment arms within a specific treatment class and is called the R_{EP} (endpoint). A strong positive correlation indicates that median PFS calibrates with median OS and is considered one form of evidence for PFS as a surrogate measure for OS (26).

The second approach, termed trial level surrogacy, computed the correlation (R_{TE}) between the reported treatment effects on PFS, the potential SEP, with the reported treatment effects on OS, and the relevant endpoint. It was similarly computed among regimens from specific treatment classes with strong positive correlation indicating the treatment effects on PFS are well calibrated to treatment

Figure 4. Treatment effects (log ORs) on PFS versus OS (months) in chemotherapy-only trials. The solid line is the regression line; dotted lines indicate pointwise 95% CIs. Symbol size is proportional to number of patients. Trial arms using comparable treatment regimens were summarized



effects on OS, so that PFS could be considered as evidence for surrogacy (27).

The 95% confidence intervals (CI) for R_{EP} and R_{TE} were obtained using the percentile bootstrap. All analyses were conducted using the R version 2.13.2 statistical package and the nlme package (R Development Core Team Vienna, Austria, 2012. Available from: <http://www.r-project.org>).

Results

All trials

For the PFS analysis, data from 50 trials representing 22,736 patients were included (refs. 28–76; Supplementary Table S1; Fig. 2). When median PFS and OS were plotted against the year of publication, a large variability without an apparent time trend was observed (data not shown). In the analysis of all treatment regimens (chemotherapy and monoclonal antibodies), treatment effects on PFS and OS were strongly correlated ($R_{TE} = 0.87$; 95% CI, 0.67–0.93), and PFS also correlated well with OS ($R_{EP} = 0.86$; 95% CI, 0.79–0.91; Table 1; Fig. 3).

Chemotherapy-only trials

Restricting the analysis to the 40 trials representing 17,887 patients, who received only cytotoxic chemotherapy

(monotherapy and combination chemotherapy), a higher correlation among treatment effects was observed, but the smaller sample size resulted in a lower 95% confidence limit ($R_{TE} = 0.93$; 95% CI, 0.49–0.97); correlation among median PFS and OS remained high ($R_{EP} = 0.81$; 95% CI, 0.71–0.88; Table 1, Fig. 4).

Oxaliplatin- and irinotecan-based trials

Among 24 trials using irinotecan-based chemotherapy, a high correlation among the treatment effects on PFS and OS was observed ($R_{TE} = 0.82$; 95% CI, 0.52–0.95) when compared with the 31 oxaliplatin-based trials ($R_{TE} = 0.68$; 95% CI, 0.41–0.85). Correlation between median PFS and OS was also higher in the irinotecan-based trials ($R_{EP} = 0.74$; 95% CI, 0.09–0.88 vs. $R_{EP} = 0.69$; 95% CI, 0.36–0.87; Table 1; figure not shown).

Trials containing monoclonal antibodies

Confinement to antibody-based regimens (4,849 patients from 19 trials) revealed weak correlation between treatment effects on PFS and OS ($R_{TE} = 0.47$; 95% CI, 0.05–0.72) and between the endpoints themselves ($R_{EP} = 0.52$; 95% CI, 0.09–0.88; Table 1; Fig. 5).




Figure 5. Treatment effects (log ORs) on PFS versus OS (months) in chemotherapy and antibody trials. The solid line is the regression line; dotted lines indicate pointwise 95% CIs. Symbol size is proportional to number of patients. Trial arms using comparable treatment regimens were summarized.

Trials containing bevacizumab

The 11 bevacizumab-based trials representing 3,310 patients exhibited a high correlation between treatment effects on PFS and OS ($R_{TE} = 0.84$; 95% CI, 0.05–0.94). In contrast, a low correlation was found between PFS and OS within this treatment group ($R_{EP} = 0.45$; 95% CI, 0.00–0.84; Table 1; Fig. 6).

Trials containing cetuximab or panitumumab

A total of 7 trials representing 1,335 patients were available for analysis. Low correlation between treatment effects on PFS and OS was found ($R_{TE} = 0.28$; 95% CI, -0.87–0.92). Correlation between PFS and OS within anti-EGFR-based trials was very high ($R_{EP} = 0.96$; 95% CI, -0.76–1.00; Table 1; Fig. 7).


Discussion

The use of PFS instead of OS as a primary endpoint in clinical trials has accelerated drug development by the earlier reporting of results, thus facilitating the more rapid introduction of new combination regimens and drugs into clinical practice. Other groups have previously investigated and validated PFS as an SEP in mCRC. A combined meta-analysis of individual patient-level data, from 10 random-

ized trials of first-line chemotherapy for mCRC revealed a strong correlation between PFS and OS (rank correlation coefficient = 0.82; 95% CI, 0.82–0.83; ref. 1). On the basis of that data, PFS was deemed to be an appropriate SEP for mCRC providing a direct measure of activity that is not affected by subsequent lines of therapy. A comprehensive literature-based analysis of 39 randomized trials conducted in 2007 also showed a strong correlation between treatment HRs for PFS and OS and further suggested that PFS could serve as a reliable SEP for OS in mCRC (6). In 2010, a review on surrogacy of PFS in breast and colorectal cancer trials recommended on the basis of evidence that PFS could serve as a validated SEP, but its role in trials with molecular-targeted agents and high rates of effective second-line treatment was questioned (5). Recently, a meta-analysis of association between PFS and OS in first- and second-line chemotherapy for mCRC revealed a robust correlation between PFS and OS across all treatment lines (23). However, the impact of targeted drug combinations on the correlation between PFS and OS, and hence the potential of PFS as a SEP for these regimens remained unanswered.

Currently, the widespread use of SEPs in first-line chemotherapy for mCRC constitutes an ongoing debate among medical oncologists, statisticians, and drug approval

Figure 6. Treatment effects (log ORs) on PFS versus OS (months) in bevacizumab-based trials. The solid line is the regression line; dotted lines indicate pointwise 95% CIs. Symbol size is proportional to number of patients. Trial arms using comparable treatment regimens were summarized.



authorities and SEPs have been validated for cytotoxic agents [5-fluorouracil (5-FU), irinotecan, and oxaliplatin combinations] only (1, 4–6).

To the best of our knowledge, this meta-analysis represents the first analysis of SEPs in mCRC that investigated monoclonal antibody trials separately, thus addressing the question of viable clinical endpoints in the targeted drug era. This quantitative review has confirmed previous findings of PFS as an acceptable SEP for cytotoxic chemotherapy regimens.

As this study focused on applicability of PFS as a potential SEP for OS in trials investigating monoclonal antibodies, all studies containing VEGF- and EGFR-directed drugs were analyzed together and weak correlations between treatment effects, PFS, and OS were found. Analyses of bevacizumab plus chemotherapy suggest that PFS might serve as a suitable SEP for these regimens with strong correlation between the treatment effects on PFS and OS (R_{TE}). Heterogeneous data among these trials yielded weak correlation among the endpoints themselves (R_{EP}) and wide 95% CIs. Of note, confirmation in a larger set of trials and at the individual patient-level is required.

At present time, 2 EGFR-inhibiting drugs, cetuximab and panitumumab, are approved for first-line chemotherapy for

mCRC. In our systematic literature search, 7 trials investigating anti-EGFR agents were evaluable. A weak correlation between the treatment effects on PFS and OS (R_{TE}) was found, whereas small sample sizes resulted in a strong correlation within PFS and OS (R_{EP}). Unfortunately, the estimated correlations are not definitive. In view of the rather large CIs, again, surrogacy in anti-EGFR-directed therapies should be further validated once more data are available. Our findings may be explained by divergent results obtained for different fluoropyrimidine backbones. Among the available trials, 4 used infusional 5-FU regimens (77–80), whereas other 3 used either capecitabine or bolus 5-FU as their chemotherapy backbone (81–83). An interaction between anti-EGFR agents and the mode of fluoropyrimidine application (oral vs. infusional) is currently discussed (84).

It is important to note that in our study only aggregated data could be analyzed. The gold standard for investigation of SEPs uses individual patient-level analyses; therefore, the meta-analytic approach used in this study can only be regarded as a first step toward this issue (85). Furthermore, we could not base our meta-analysis on measures of treatment effects, such as HRs, as studies comparing identical treatment classes did not permit the estimation of HRs (86).




Figure 7. Treatment effects (log ORs) on PFS versus OS (months) in cetuximab or panitumumab-based trials. The solid line is the regression line; dotted lines indicate pointwise 95% confidence intervals. Symbol size is proportional to number of patients. Trial arms using comparable treatment regimens were summarized.

Another limitation of the present study is the variety of disease assessment times and different definitions of disease progression. This remains a common issue when comparing trials using PFS as a clinical endpoint (7). In addition, only few publications reported postprogression treatment or surgical metastasectomy, both of which constitute important determinants of survival (87). Standardized reporting of trial results is essential in the future design of randomized trials.

A recent study reported on different alternative endpoints in advanced colorectal cancer and conducted a pooled analysis of 3 randomized trials at the individual patient-level (86). Composite endpoints, such as duration of disease control and time to failure of strategy showed good correlation with OS, whereas PFS failed to show acceptable correlation. Adding the PFS of second and subsequent lines of therapy can possibly restore the surrogacy between the treatment effects and OS. The discordant findings to the present study emphasize the need for further confirmation at the individual patient-level, once more data from anti-EGFR- and anti-VEGF-based trials are available.

The present analysis of 50 trials has confirmed the use of PFS as an applicable SEP for OS in first-line treatment of mCRC using chemotherapy alone. Results from bevacizu-

mab-based trials seemed to show satisfying surrogacy of PFS. Findings obtained for trials investigating anti-EGFR directed agents have to be confirmed once a larger database is available. Additional endpoints in mCRC including tumor- or patient-related biomarkers, as have been successfully implemented in other diseases, and investigation of these potential SEPs is strongly encouraged.

Disclosure of Potential Conflicts of Interest

C. Giessen has travel support from Roche. S. Stintzing has honoraria from speakers bureau of Merck Serono, Roche AG, and Amgen. D.P. Modest is a consultant/advisory board member of Amgen and has expert testimony from Amgen, Merck, and Roche. V. Heinemann has honoraria from speakers bureau and is a consultant/advisory board member of Merck, Roche, Amgen, and Sanofi. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: C. Giessen, R.P. Laubender, U. Mansmann, V. Heinemann

Development of methodology: C. Giessen, R.P. Laubender, U. Mansmann, V. Heinemann

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): C. Giessen, V. Heinemann

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): C. Giessen, R.P. Laubender, D.P. Ankerst, S. Stintzing, U. Mansmann, V. Heinemann

Writing, review, and/or revision of the manuscript: C. Giessen, R.P. Laubender, D.P. Ankerst, S. Stintzing, D.P. Modest, U. Mansmann, V. Heinemann

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Giessen, V. Heinemann
Study supervision: C. Giessen, V. Heinemann

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked

advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 9, 2012; revised October 22, 2012; accepted October 29, 2012; published OnlineFirst November 13, 2012.

References

- Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. *J Clin Oncol* 2007;25:5218–24.
- Methy N, Bedenne L, Bonnetain F. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaire survey among clinicians and methodologists. *BMC Cancer* 2010;10:277.
- Piedbois P, Buyse M. Endpoints and surrogate endpoints in colorectal cancer: a review of recent developments. *Curr Opin Oncol* 2008;20:466–71.
- Piedbois P, Miller Crowell J. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective. *Stat Methods Med Res* 2008;17:519–27.
- Saad ED, Katz A, Hoff PM, Buyse M. Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. *Ann Oncol* 2010;21:7–12.
- Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. *J Clin Oncol* 2007;25:4562–8.
- Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, et al. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. *Curr Oncol* 2011;18(Suppl 2):S5–S10.
- Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? *J Clin Oncol* 2012;30:1750–4.
- Booth CM, Eisenhauer EA. Progression-free survival: meaningful or simply measurable? *J Clin Oncol* 2012;30:1030–3.
- Grothey A, Sargent D, Goldberg RM, Schmoll H-J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. *J Clin Oncol* 2004;22:1209–14.
- Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? *Ann Intern Med* 1996;125:605–13.
- Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. *J Clin Oncol* 2003;21:1404–11.
- Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. *Stat Med* 1989;8:431–40.
- Prentice RL. Surrogate and mediating endpoints: current status and future directions. *J Natl Cancer Inst* 2009;101:216–7.
- Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anticancer drugs. *Cancer Treat Rep* 1985;69:1155–9.
- Buyse M, Molenberghs G. Criteria for the validation of surrogate endpoints in randomized experiments. *Biometrics* 1998;54:1014–29.
- Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H. The validation of surrogate endpoints in meta-analyses of randomized experiments. *Biostatistics* 2000;1:49–67.
- Freedman LS, Graubard BI, Schatzkin A. Statistical validation of intermediate endpoints for chronic diseases. *Stat Med* 1992;11:167–78.
- Saad ED, Katz A. Progression-free survival and time to progression as primary end points in advanced breast cancer: often used, sometimes loosely defined. *Ann Oncol* 2009;20:460–4.
- Toi J, Punt CJ. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. *Clin Ther* 2010;32:437–53.
- Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
- Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. *J Clin Oncol* 2010;28:1958–62.
- Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, et al. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. *Int J Colorectal Dis* 2012;27:623–34.
- Burzykowski T, Molenberghs G, Buyse M, Geys H, Renard D. Validation of surrogate end points in multiple randomized clinical trials with failure time end points. *J R Stat Soc: Ser C (Appl Stat)* 2001;50:405–22.
- Ghosh D, Taylor JM, Sargent DJ. Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling. *Biometrics* 2012;68:226–32.
- Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 2—correlation between subjects. *BMJ* 1995;310:633.
- Bland JM, Altman DG. Statistics notes: calculating correlation coefficients with repeated observations: part 1—correlation within subjects. *BMJ* 1995;310:446.
- Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* 2001;19:2282–92.
- Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* 2001;19:4097–106.
- Kohne CH, Wils J, Lorenz M, Schoffski P, Voigtmann R, Bokemeyer C, et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. *J Clin Oncol* 2003;21:3721–8.
- Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000;355:1041–7.
- Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000;343:905–14.
- Kohne CH, van Cutsem E, Wils J, Bokemeyer C, El-Serafi M, Lutz MP, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. *J Clin Oncol* 2005;23:4856–65.
- Aranda E, Valladares M, Martinez-Villacampa M, Benavides M, Gomez A, Massutti B, et al. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. *Ann Oncol* 2009;20:251–7.
- Glimelius B, Sorbye H, Balteskard L, Bystrom P, Pfeiffer P, Tveit K, et al. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. *Ann Oncol* 2008;19:909–14.
- Labianca R, Sobrero A, Isa L, Cortesi E, Barni S, Nicoletta D, et al. Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial. *Ann Oncol* 2011;22:1236–42.
- Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to

- chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2000;18:136–47.
38. de Gramont A, Figuer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 2000;18:2938–47.
 39. Grothey A, Deschler B, Kroening H, Ridwelski K, Reichardt P, Kretzschmar A, et al. Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). *Proc Am Soc Clin Oncol* 21: 2002 (abstr 512).
 40. Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. *Ann Oncol* 2010;21:87–91.
 41. Diaz-Rubio E, Tabernero J, Gomez-Espana A, Massuti B, Sastre J, Chaves M, et al. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial. *J Clin Oncol* 2007;25:4224–30.
 42. Cunningham D, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynn-Jones R, et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. *Ann Oncol* 2009;20:244–50.
 43. Tournigand C, Cervantes A, Figuer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study. *J Clin Oncol* 2006;24:394–400.
 44. Giacchetti S, Bjarnason G, Garufi C, Genet D, Iacobelli S, Tampellini M, et al. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group. *J Clin Oncol* 2006;24:3562–9.
 45. Hespers GA, Schaapveld M, Nortier JW, Wils J, van Bochove A, de Jong RS, et al. Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. *Ann Oncol* 2006;17:443–9.
 46. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. *J Clin Oncol* 2007;25:4217–23.
 47. Ducreux M, Bennouna J, Hebbar M, Ychou M, Lledo G, Conroy T, et al. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. *Int J Cancer* 2011;128:682–90.
 48. Ducreux M, Malka D, Mendiboure J, Etienne PL, Texereau P, Auby D, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2011;12:1032–44.
 49. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figuer A, Wong R, et al. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. *Br J Cancer* 2011;105:58–64.
 50. Tournigand C, Andre T, Achille E, Lledo G, Flesch M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004;22:229–37.
 51. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. *J Clin Oncol* 2005;23:4866–75.
 52. Comella P, Massidda B, Filippelli G, Palmeri S, Natale D, Farris A, et al. Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. *Ann Oncol* 2005;16:878–86.
 53. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. *Lancet* 2007;370:143–52.
 54. Koopman M, Antonini NF, Douma J, Wals J, Honkoop AH, Erdkamp FL, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet* 2007;370:135–42.
 55. Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambert H, et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. *Eur J Cancer* 2011;47:206–14.
 56. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williams SK, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004;22:23–30.
 57. Ashley AC, Sargent DJ, Alberts SR, Grothey A, Campbell ME, Morton RF, et al. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX): intergroup trial N9741 in first-line treatment of metastatic colorectal cancer. *Cancer* 2007;110:670–7.
 58. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). *Br J Cancer* 2006;94:798–805.
 59. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol* 2007;25:1670–6.
 60. Masi G, Vasile E, Loupakis F, Cupini S, Fornaro L, Baldi G, et al. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. *J Natl Cancer Inst* 2011;103:21–30.
 61. Kabbinnar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. *J Clin Oncol* 2005;23:3697–705.
 62. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004;350:2335–42.
 63. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figuer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. *J Clin Oncol* 2008;26:2013–9.
 64. Ducreux M, Adenis A, Mendiboure J, Francois E, Boucher E, Chauffert B, et al. Efficacy and safety of bevacizumab (BEV)-based combination regimens in patients with metastatic colorectal cancer (mCRC): randomized phase II study of BEV + FOLFIRI versus BEV + XELIRI (FNCLCC ACCORD 13/0503 study). *J Clin Oncol* 27:15s, 2009 (suppl; abstr 4086).
 65. Tebbutt NC, Wilson K, Gebbski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. *J Clin Oncol* 2010;28:3191–8.
 66. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. *Oncologist* 2012;17:15–25.

67. Pectasides D, Papaxoinis G, Kalogeras K, Eleftheraki A, Xanthakis I, Makatsoris T, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. *BMC Cancer* 2012;12:271.
68. Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. *Chin J Cancer* 2011;30:682–9.
69. Souglakos J, Ziras N, Kakolyris S, Boukovinas I, Kentepozidis N, Makrantonakis P, et al. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). *Br J Cancer* 2012;106:453–9.
70. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *J Clin Oncol* 2011;29:2011–9.
71. Maughan TS, Adams R, Smith CG, Seymour MT, Wilson RH, Meade AM, et al. Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): mature results of the MRC COIN trial. *J Clin Oncol* 28:15s, 2010 (suppl; abstr 3502).
72. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet Oncol* 2011;12:642–53.
73. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27:663–71.
74. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 2009;27:672–80.
75. Saltz L, Badarinarath S, Dakhil S, Bienvu B, Harker WG, Birchfield G, et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. *Clin Colorectal Cancer* 2012;11:101–11.
76. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *N Engl J Med* 2009;360:563–72.
77. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zuber A, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 2011;22:1535–46.
78. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. *J Clin Oncol* 2010;28:4697–705.
79. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–17.
80. Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. *World J Gastroenterol* 2010;16:3133–43.
81. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011;377:2103–14.
82. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104—a randomized trial of the German AIO CRC study group. *J Clin Oncol* 2011;29:1050–8.
83. Tveit K, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. LBA20—randomized phase III study of 5-fluorouracil/folinic acid/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: the nordic VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. *Ann Oncol ESMO* 2010 late-breaking abstracts LBA 20. 2010;21(Suppl 8):LBA20.
84. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer treatment continuum—applying current evidence to clinical practice. *Cancer Treat Rev* 2012;38:397–406.
85. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. *J Clin Oncol* 2004;22:3839–41.
86. Chibaudel B, Bonnetain F, Shi Q, Buyse M, Tournigand C, Sargent DJ, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy—an Aide et Recherche en Cancérologie Digestive Group Study. *J Clin Oncol* 2011;29:4199–204.
87. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. *J Clin Oncol* 2009;27:3677–83.